Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
6/30/18 cash was $38.6M (€33.1M) after burning $3.0M (€2.6M) during 2Q18. Guidance for 2H18 cash burn is $19.4M (€16.6M), implying projected a cash balance at 12/31/18 of $19.2M.
TNG.PA* starts phase-2 trial of TG4010 cancer vaccine in combination with Opdivo and chemotherapy in first-line, non-squamous NSCLC patients with low (or no) PD-L1 expression: